Subacute Cutaneous Lupus Erythematosus Associated with Ramucirumab Therapy

Main Article Content

Elise Hogan
University of Cincinnati College of Medicine

Kelsey Nusbaum
University of Cincinnati College of Medicine

Anne Householder
University of Cincinnati College of Medicine

Keywords

subacute cutaneous lupus erythematosus, lupus, rash, monoclonal antibodies, ramucirumab, cytotoxic dermatitis, drug-induced, drug-induced SCLE

Abstract

Abstract not available. 

References

1. Cojocaru, M., Cojocaru, I. M., Silosi, I., & Vrabie, C. D. Manifestations of systemic lupus erythematosus. Maedica, (2011), 6(4), 330–336. [PMID: 22879850]

2. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985 Jul;103(1):49-51. [PMID: 3873891].

3. Bolton C, Chen Y, Hawthorne R, et al. Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus. Drugs R D. 2020 Dec;20(4):319-330. [PMID: 32960413].

4. Zhu AX, Kang YK, Yen CJ, et al. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296. [PMID: 30665869].

5. Cleaver N, Ramirez J, Gildenberg S. Cutaneous lupus erythematosus in a patient undergoing intravitreal bevacizumab injections: case report and review of the literature. J Drugs Dermatol. 2013 Sep;12(9):1052-5. [PMID: 24002156].

6. Andric M, Dixit S, Robaei D, Watchorn R, Verma N. A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment. Indian J Ophthalmol. 2013 Dec;61(12):752-4. [PMID: 24212210].

Article Sidebar

PDF
Published
Mar 4, 2022
DOI https://doi.org/10.25251/skin.6.2.17

Article Details

How to Cite
Hogan, E., Nusbaum, K., & Householder, A. (2022). Subacute Cutaneous Lupus Erythematosus Associated with Ramucirumab Therapy. SKIN The Journal of Cutaneous Medicine, 6(2), 174–176. https://doi.org/10.25251/skin.6.2.17
Issue
Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Section
Short Communications
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.